Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health Inc. (OTCQB: ODYY) is a medical company focused on life-saving and life-enhancing medical solutions, and its news flow reflects this emphasis on critical care and diagnostic technologies. Company announcements highlight development milestones, licensing transactions, financing arrangements and strategic asset sales that shape its evolving portfolio.
Recent news has detailed Odyssey’s entry into the breast cancer diagnostics marketplace through a Master Technology and Sub-license Agreement for exclusive, worldwide rights to BreastCheck ae, a non-invasive test for breast abnormalities. Press releases describe BreastCheck ae as a home-use, temperature-based screening tool that provides results in about 15 minutes and is intended to complement established diagnostic procedures. Updates also cover regulatory status, including FDA registration in the United States and registrations with authorities in the European Union and the United Kingdom.
Odyssey’s news archive also covers progress on its Save A Life choking rescue device, a patented vacuum-based system designed to dislodge airway obstructions rapidly. The company has reported creating a prototype and planning further development with the goal of an FDA submission, illustrating how it communicates development stages and regulatory intentions to investors and stakeholders.
Another key theme in Odyssey’s news is corporate and financial strategy. Releases describe the sale of its neurological drug technology pipeline, including the concussion candidate ONP-002, to Oragenics, Inc., as well as the resulting investment in Oragenics preferred stock. Additional coverage explains long-term service contracts and financing facilities, such as the multi-year maintenance service agreement and related funding capacity with Mast Hill Fund, L.P., which the company characterizes as supporting its transition toward recurring revenue and commercialization initiatives.
Investors and observers can use the ODYY news page on Stock Titan to follow these developments, including device development updates, licensing agreements, regulatory steps, financing transactions and portfolio changes that may influence Odyssey Health’s business trajectory.
Odyssey Group International (OTCQB: ODYY) announced a significant milestone in developing its concussion drug, PRV-002. The completion of FDA-required toxicology studies has set the stage for a Phase 1 clinical trial, contracted with Nucleus Network in Australia. Preclinical studies suggest PRV-002 has a safety margin over 100-fold the intended dosing, preparing the company for clinical trials this summer. The data will support their Investigational New Drug Application (IND) with the FDA, paving the way for future Phase 2 trials in the US.
Odyssey Group International, Inc. (OTCQB: ODYY) has announced its Annual Meeting of Stockholders scheduled for June 30, 2021. Stockholders must submit proposals by June 3, 2021, to be considered at the meeting. The official Notice of Annual Meeting and Proxy Statement will be filed with the SEC after the Board reviews any received proposals. Odyssey is dedicated to developing life-saving medical products and aims to create distinct assets and technologies to deliver significant medical solutions and returns for shareholders.
Odyssey Group International has announced the successful development of a novel nasal drug delivery device for its concussion treatment candidate, PRV-002. Collaborating with Design Catapult, Inc., the device aims to enhance drug bio-distribution to the brain. It is set for use in phase 1 clinical trials scheduled in Australia this summer. Odyssey's CEO, Michael Redmond, highlights this milestone as crucial for administering PRV-002. The device has completed validation and will be manufactured under Good Manufacturing Practices.
Odyssey Group International, Inc. (OTCQB: ODYY) announced the appointment of Ricky Richardson to its Board of Directors. With over 30 years in operations and quality management, Richardson's previous roles include Corporate Director at Danaher Corporation and Director of Operations at Stryker Orthopaedics. His extensive experience in R&D and quality control is expected to enhance Odyssey's product development efforts, contributing to their mission of creating innovative medical solutions. The company focuses on leveraging technological advantages in the medical field.
Odyssey Group International, Inc. (OTCQB: ODYY) welcomes Dr. Bob Arnot to its Scientific Advisory Board, aiming to advance innovative medical solutions for brain injury. Dr. Arnot, an award-winning journalist and author, brings extensive experience in clinical trials and medical technology. He will guide the development of PRV-002, a neurosteroid for treating concussions, currently in pre-clinical phase. The board consists of esteemed professionals, aiming to address unmet medical needs. CEO Michael Redmond expressed enthusiasm for Arnot's contributions in improving outcomes for concussion patients.
Odyssey Group International, Inc. (OTCQB: ODYY) has established a Scientific Advisory Board (SAB) comprising experts in neurology, cardiology, and preclinical drug development to guide the company in advancing its medical product portfolio. The SAB will assist in the development of PRV-002, a drug candidate for concussion treatment, expected to enhance R&D and clinical efforts. Founding members include prominent figures with extensive military and clinical research backgrounds, aiming to address significant medical needs.
Odyssey Group International welcomes Abby Wambach, former U.S. National Soccer Team captain, to its Sports Advisory Board to increase awareness of the need for treatments for brain injuries, including concussions. The Sports Advisory Board consists of various notable athletes working to support the company’s outreach. Odyssey is in the pre-clinical phase of developing PRV-002, a drug compound aimed at treating mild traumatic brain injuries (concussions), preparing for its first human clinical trial. CEO Michael Redmond emphasized the critical need for effective concussion treatments.
Odyssey Group International (OTCQB:ODYY) announced that CEO Michael Redmond will present at the Q1 Virtual Investor Summit on March 24, 2021, at 2:30 PM ET. The summit will feature various small- and mid-cap companies connecting with over 300 qualified investors. Redmond will discuss Odyssey's strategy regarding life-saving medical products, specifically its drug candidate PRV-002, intended for treating concussion. The event highlights Odyssey's commitment to developing innovative medical solutions.
Odyssey Group International (OTCQB: ODYY) has formed a Sports Advisory Board (SAB) to enhance awareness of brain injuries and the need for FDA-approved treatments. The SAB features prominent athletes like Kurt Warner and Brett Favre, who aim to address the issue of concussions, emphasizing the development of PRV-002, a drug currently in pre-clinical trials. CEO Michael Redmond highlighted the pressing need for effective therapies for traumatic brain injuries.
Odyssey Group International, Inc. (OTCQB:ODYY) announced that Dr. Jake VanLandingham will appear on NewsNation Now's 'The Donlon Report' with Brett Favre to discuss PRV-002, a novel treatment for concussions. The segment airs at 7:30 PM ET on March 10, 2021. Dr. VanLandingham expressed enthusiasm over the media attention PRV-002 is receiving as the company gears up for human clinical trials. PRV-002, a synthetic neurosteroid, shows promise in preclinical studies, demonstrating neuroprotective effects that could benefit those suffering from mild traumatic brain injury.